摘要
目的:观察和对比丽珠胃三联一周及两周疗法临床疗效。方法:对HP阳性病人246例分别予丽珠胃三联(丽珠得乐220mg,克拉霉素250mg,替硝唑(500mg),连服一周及两周,治疗结束停药4周后,胃镜检查HPUT及病理W-S银染阴性率。结果:服用丽珠胃三联一周病人(123例),HPUT及W-S银染阴性111例,HP根除率90.2％。结论:服用丽珠胃三联1周及2周病人的HP根除率及临床疗效相似,P>0.05。
Objective: To investigate and evaluate the efficacy of one-week and two-week therapies with Livzon WeiSanLian for the treatment of H.pylori infection. Methods: 246 patients with H.pylori infection were randomised into two groups. GroupA received Livzon WeiSanLian (Bismuth potassium citrate 220mg, clarythromycin 250 mg, Tinidazole 500mg) for one week twice daily, and group B received Livzon WeiSanLian for two weeks twice daily. Endoscopic examination was carried four weeks after cessation of the treatment. The H.pylori status was determined by rapid urease test (HPUT) and warthin-starry stain. Results: the eradication rate of group A was 88.6% and the eradication rate of group B was 90.2%, P>0.05. Conclusions: The H.pylori eradication rate of one-week therapy with Livzon WeiSanLian is similar to that of two-week therapy, and the one-week therapy with Livzon WeiSanLian should be the first project for H.pylori eradication.
出处
《当代医学》
2002年第1期84-85,共2页
Contemporary Medicine
关键词
丽珠胃三联
HP
根除率
Livzon WeiSanLian, helicobacter pylori, eradication rate
